Contributions
Abstract: EP1348
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Introduction: Multiple sclerosis is characterized by a non-homogeneous distribution around the world. There are no system epidemiological data for multiple sclerosis (MS) in Saint-Petersburg.
Objective: To calculate the incidence and the prevalence of multiple sclerosis (MS) in Saint-Petersburg (located in North-West region of Russia).
Methods: This is an observational, cross-sectional, descriptive study. The City Center of MS was founded in October 2011. This is the first center in Russia conducting electronic health records, which allowed us to estimate the incidence and the prevalence of MS in St. Petersburg with the city population of just over 5 million. Patients (n=3150) with definite MS according to McDonald criteria 2010 were included in the study on March 1, 2017.
Results: The incidence rate in 2016y for St. Petersburg was 6,4/10^5 and prevalence rate was 60/10^5 . It´s noted a gradual increase in the incidence of the MS with 1-2/10^5 (2000-2007y) to 4,9/10^5 (2011y) and 6.4/105 (2016y).70 % of patients with relapsing- onset MS and 50 % patients with progressive onset MS are women (sex ratio for RRMS m:f = 1:2,3). Types of MS distribution in our Center is 80% for RRMS, SPMS - 14% and PPMS - 6 %. The diagnosis was done at mean age of 34 with relapsing-onset MS and 45 with progressive-onset MS (p < 0,0001). Men are diagnosed on average two years earlier than women (p < 0,0001). Depending on the type of MS at the Center of observed patients with RRMS in younger age group (peak is 20-40 years, p < 0,0001), older patients more often have progressive type (SPMS and PPMS, p > 0,08) with peak of 40-60 years. 70 % of MS patients (n=2205) receive DMD, among them 36% - glatiramer acetate, 50 % - interferones, 5% - natalizumab and others - fingolimod, mitoxantrone, cyclophosphamide, rituximab, azathioprine and in clinical trials.
The incidence of pediatric MS (< 18 years) is 1,01/10^5 and the prevalence is 3,0/10^5 . About 10% patients had a first relapse in pediatric age, 2/3 of them was diagnosed of MS after18 years. Only 2 patients with PPMS (less then 1 %) had onset before 18 years.
Conclusion: According to our study results St. Petersburg has high prevalence rate of MS. Increased incidence warrants further observation to clarify the truth of the growth and elimination of factors influencing a better detectability of MS and accessibility of health care.
Disclosure:
M Shumilina: nothing to disclose.
E Evdoshenko: support fees for board membership, consultancy or speaking, or grants, from Biogen Idec, Sanofi-Aven s, Genzyme, Pharmstandart, R-Pharm, Pharmsyntez, Genfa Medica, Takeda and Generium.
A.A. Scoromets: financial support from Roche, Genzyme/Sanofi, Novartis, Teva, Janssen
Abstract: EP1348
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Introduction: Multiple sclerosis is characterized by a non-homogeneous distribution around the world. There are no system epidemiological data for multiple sclerosis (MS) in Saint-Petersburg.
Objective: To calculate the incidence and the prevalence of multiple sclerosis (MS) in Saint-Petersburg (located in North-West region of Russia).
Methods: This is an observational, cross-sectional, descriptive study. The City Center of MS was founded in October 2011. This is the first center in Russia conducting electronic health records, which allowed us to estimate the incidence and the prevalence of MS in St. Petersburg with the city population of just over 5 million. Patients (n=3150) with definite MS according to McDonald criteria 2010 were included in the study on March 1, 2017.
Results: The incidence rate in 2016y for St. Petersburg was 6,4/10^5 and prevalence rate was 60/10^5 . It´s noted a gradual increase in the incidence of the MS with 1-2/10^5 (2000-2007y) to 4,9/10^5 (2011y) and 6.4/105 (2016y).70 % of patients with relapsing- onset MS and 50 % patients with progressive onset MS are women (sex ratio for RRMS m:f = 1:2,3). Types of MS distribution in our Center is 80% for RRMS, SPMS - 14% and PPMS - 6 %. The diagnosis was done at mean age of 34 with relapsing-onset MS and 45 with progressive-onset MS (p < 0,0001). Men are diagnosed on average two years earlier than women (p < 0,0001). Depending on the type of MS at the Center of observed patients with RRMS in younger age group (peak is 20-40 years, p < 0,0001), older patients more often have progressive type (SPMS and PPMS, p > 0,08) with peak of 40-60 years. 70 % of MS patients (n=2205) receive DMD, among them 36% - glatiramer acetate, 50 % - interferones, 5% - natalizumab and others - fingolimod, mitoxantrone, cyclophosphamide, rituximab, azathioprine and in clinical trials.
The incidence of pediatric MS (< 18 years) is 1,01/10^5 and the prevalence is 3,0/10^5 . About 10% patients had a first relapse in pediatric age, 2/3 of them was diagnosed of MS after18 years. Only 2 patients with PPMS (less then 1 %) had onset before 18 years.
Conclusion: According to our study results St. Petersburg has high prevalence rate of MS. Increased incidence warrants further observation to clarify the truth of the growth and elimination of factors influencing a better detectability of MS and accessibility of health care.
Disclosure:
M Shumilina: nothing to disclose.
E Evdoshenko: support fees for board membership, consultancy or speaking, or grants, from Biogen Idec, Sanofi-Aven s, Genzyme, Pharmstandart, R-Pharm, Pharmsyntez, Genfa Medica, Takeda and Generium.
A.A. Scoromets: financial support from Roche, Genzyme/Sanofi, Novartis, Teva, Janssen